招商證券(06099.HK)附屬擬出資15億元參設合夥企業
格隆匯4月18日丨招商證券(06099.HK)宣佈,於2022年4月18日,公司全資附屬招商證券投資(作為有限合夥人)與招商國協(作為普通合夥人)、招商局資本控股(作為有限合夥人)及南通招華(作為有限合夥人)訂立合夥協議,共同成立南通招華招證股權投資合夥企業(有限合夥)。
據此,合夥企業出資總額為人民幣16.01101億元,其中招商證券投資出資人民幣15億元、招商局資本控股出資人民幣1億元、南通招華出資人民幣100.1萬元及招商國協出資人民幣10萬元。成立合夥企業旨在主要投資於多個行業領域,包括但不限於科技、互聯網、消費、醫療保健及教育。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.